The Technical Analyst
Adaptimmune Therapeutics [ADAP]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Adaptimmune Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.86% $2.34
Last updated: 7 aug 2022 - 23:46
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 382.29 mill |
| EPS: | -1.092 |
| P/E: | 0.000 |
| Earnings Date: | Aug 04, 2022 |
| SharesOutstanding: | 163.37 mill |
| Avg Daily Volume: | 0.374 mill |
| RATING 2022-08-05 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.30 (41.13%) $0.962 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.18 - 2.50 ( +/- 6.84%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-08-01 | Piccina Cintia | Sell | 21 040 | American Depositary Shares representing Ordinary Shares |
| 2022-08-01 | Lunger John | Sell | 2 983 | American Depositary Shares representing Ordinary Shares |
| 2022-07-05 | Lunger John | Sell | 1 973 | American Depositary Shares representing Ordinary Shares |
| 2022-07-01 | Behbahani Ali | Buy | 737 050 | Option to purchase Ordinary Shares |
| 2022-07-01 | Mott David M | Buy | 1 000 439 | Option to purchase Ordinary Shares |
| INSIDER POWER |
|---|
| 98.44 |
| Last 100 transactions |
| Buy: 43 489 933 | Sell: 353 096 |
Forecast:
16:00 - $2.34
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.34
Forecast 2: 16:00 - $2.34
Forecast 3: 16:00 - $2.34
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.34 (0.86% ) |
| Volume | 0.260 mill |
| Avg. Vol. | 0.374 mill |
| % of Avg. Vol | 69.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ADAP
165 Signals | Accuracy: 13.94% | Accuracy Buy: 14.63% | Accuracy Sell: 13.25%
Avg return buy: -0.43 % | Avg return sell: 0.74 %
$1 invested is now $0.70 or -30.41% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 15:54 | buy | $2.32 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 15:53 | sell | $2.32 | $2.32 @ Aug 5 - 15:54 | 0.22% |
| Aug 5 - 15:40 | buy | $2.32 | $2.32 @ Aug 5 - 15:53 | -0.22% |
| Aug 5 - 15:04 | sell | $2.30 | $2.32 @ Aug 5 - 15:40 | 0.87% |
| Aug 5 - 14:54 | buy | $2.31 | $2.30 @ Aug 5 - 15:04 | -0.43% |
| Aug 5 - 13:44 | sell | $2.34 | $2.31 @ Aug 5 - 14:54 | -1.07% |
| Aug 5 - 13:41 | buy | $2.34 | $2.34 @ Aug 5 - 13:44 | -0.21% |
| Aug 5 - 13:35 | sell | $2.33 | $2.34 @ Aug 5 - 13:41 | 0.43% |
| Aug 5 - 13:32 | buy | $2.34 | $2.33 @ Aug 5 - 13:35 | -0.53% |
| Aug 5 - 13:02 | sell | $2.35 | $2.34 @ Aug 5 - 13:32 | -0.32% |
ADAP
Latest Press Releases
2022-08-04 07:30:00 - Press Release
Adaptimmune Reports Second-quarter Financial Results And Business Update
- reaffirming financial guidance; company funded into early 2024 -- asco data confirms afami-cel potential for synovial sarcoma; bla submission on-track for q4 2022 - - update from signal-finding phase 1 surpass trial at the september esmo 2022 congress - - quarterly call to be held today, august 4, 2022, at 8:00 a.m. edt (1:00 p.m. bst) -philadelphia, pennsylvania, and oxford, united kingdom--(newsfile corp.
2022-05-26 17:00:00 - Press Release
Clinical Responses Reported Across Patient Subgroups With Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential For People With Rare Sarcomas - Bla Submission On-track
- patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) -- responses occurred across subgroups, with greater response rates associated with lower baseline tumor burden, fewer prior lines of therapy, and higher mage-a4 expression -- afami-cel demonstrated a favorable benefit:risk profile -philadelphia, pennsylvania and oxford, united kingdom--(newsfile corp. - may 26, 2022) - adaptimmune therapeutics plc (nasdaq: adap), a leader in cell therapy to treat cancer,...
2022-05-16 17:00:00 - Press Release
Preclinical Proof-of-concept Data Supporting Future Clinical Development Of Two New Cell Therapies Being Presented By Adaptimmune At Asgct
- new next-gen spear t-cells (adp-a2m4n7x19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro -
2022-05-09 07:30:00 - Press Release
Adaptimmune Reports First Quarter Financial Results And Business Update
- pooled data from cohort 1 of the spearhead-1 trial and the phase 1 trial of afami-cel in patients with sarcoma to be presented as a poster at asco -
2022-05-04 08:00:00 - Press Release
Adaptimmune Announces Appointment Of Joanna Brewer As Chief Scientific Officer
Philadelphia and oxfordshire, united kingdom, may 04, 2022 (globe newswire) -- adaptimmune therapeutics plc (nasdaq:adap), a leader in t-cell therapy to treat cancer, today announces the appointment of dr. joanna (jo) brewer as chief scientific officer (cso) effective immediately.
Latest News
2022-08-06 23:39:02 - Seeking Alpha
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late Stage Development Gavin Wood - Chief Financial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Tony Butler - Roth Anthony Rodriguez - Cowen & Company Jonathan Chang - SVP Leerink Mara Goldstein - Mizuho Securities Danya Hail - Jones Research Operator Good morning, everyone. Welcome to the Adaptimmune's Q2 Financial and Business Update Conference Call.
2022-07-01 16:45:00 - The Motley Fool
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
2022-06-29 05:59:28 - Seeking Alpha
Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the treatment of patients with synovial sarcoma and MRCLS is expected in Q4 of 2022.
2022-06-27 15:27:06 - The Motley Fool
Why Adaptimmune Therapeutics Stock Is Popping Today
2022-06-19 06:35:52 - Seeking Alpha
Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell that targets the MAGE-A4 CTA and is being tried in multiple tumors types.
2022-05-17 17:03:27 - The Motley Fool
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.
2022-05-09 13:57:11 - Seeking Alpha
Adaptimmune Therapeutics' (ADAP) CEO Adrian Rawcliffe on Q1 2022 Results - Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2022 Earnings Conference Call May 9, 2022 8:00 AM ET Company Participants Juli Miller – Head-Investor Relations Adrian Rawcliffe – Chief Executive Officer Gavin Wood – Chief Financial Officer Helen Tayton-Martin – Chief Business Officer John Lunger – Chief Patient Supply Officer Elliot Norry – Chief Medical Officer Cintia Piccina – Chief Commercial Officer Conference Call Participants Marc Frahm – Cowen and Company Tony Butler – ROTH Capital Faisal Khurshid – SVB Securities Nick Abbott – Wells Fargo Mara Goldstein – Mizuho Operator Good morning and thank you for standing by. Welcome to the First Quarter 2022 Adaptimmune Earnings Conference Call.
2022-04-26 09:02:33 - Zacks Investment Research
New Strong Sell Stocks for April 26th
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
2022-04-22 10:32:13 - Zacks Investment Research
New Strong Sell Stocks for April 22nd
BBBY, CLGN, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 22, 2022
2022-04-19 15:43:02 - The Motley Fool
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped Today
Regeneron's buyout of Checkpoint Pharmaceuticals is sparking a rally among clinical-stage cancer research companies today.